


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:


LISTING OF CLAIMS:

1. **(Original)** A compound represented by formula (I).



wherein ring A, ring B and ring D each independently represents a cyclic group which may have a substituent(s); W represents a spacer having 1 to 8 atom(s) in its main chain; X represents a spacer having 1 to 2 atom(s) in its main chain; Y represents a binding bond or a spacer having 1 to 8 atom(s) in its main chain; and Z represents an acidic group, or a salt thereof, a solvate thereof or a prodrug thereof.


2. **(Original)** The compound according to claim 1, which is represented by formula (IC):



wherein ring A^a, ring B^a and ring D^a each independently represents a C5-10 monocyclic or bicyclic carbon ring which may have a substituent(s), or a 5- to 10-membered monocyclic or bicyclic heterocyclic ring containing 1 to 3 hetero atoms selected from an oxygen atom, a nitrogen atom and/or a sulfur atom; X^a represents -O-, -S-, -CO- or -CONR²-, in which R² represents a hydrogen atom, a hydrocarbon group which may have a substituent(s) or a cyclic group which may have a substituent(s); Y^a is a binding bond or methylene which may have a substituent(s); Z^a represents carboxyl which may be esterified; R¹ represents C1-6 alkylene, C2-6 alkenylene or C2-6 alkynylene; and M represents a spacer having 1 or 2 atoms in its main chain selected from an oxygen atom, carbonyl and a nitrogen atom which may have a substituent(s), or a salt thereof, a solvate thereof or a prodrug thereof.


3. **(Original)** The compound according to claim 1, wherein ring A is a benzene, a pyridine, oxazole or thiazole ring which may have a substituent(s); ring B is a benzene or pyridine ring which may have a substituent(s); ring D is a benzene or pyridine ring which may have a substituent(s); W is $-R^{1a}-M^a-$, in which R^{1a} is propylene, propenylene or propynylene, and M^a is $-O-$, $-NH-$, $-NHCO-$ or $-CONH-$; X represents $-O-$ or $-CONR^2-$, in which R^2 represents a hydrogen atom, a hydrocarbon group which may have a substituent(s) or a cyclic group which may have a substituent(s); Y is a binding bond or methylene; and Z is carboxyl which may be esterified, or a salt thereof, a solvate thereof or a prodrug thereof.

4. **(Original)** The compound according to claim 2, which is represented by formula (ID):




wherein ring B^{a1} and ring D^{a1} each independently represents a benzene ring which may have a substituent(s); and other symbols have the same meanings as described in claim 2, or a salt thereof, a solvate thereof or a prodrug thereof.

5. **(Original)** The compound according to claim 2, which is represented by formula (IE):



wherein all symbols have the same meanings as described in claim 2, or a salt thereof, a solvate thereof or a prodrug thereof.

6. **(Original)** The compound according to claim 2, which is represented by formula (IF):



wherein all symbols have the same meanings as described in claim 2, or a salt thereof, a solvate thereof or a prodrug thereof.

7. **(Original)** The compound according to claim 1, which is selected from the group consisting of:

- (1) {4-methoxy-3-[3-({(2E)-3-[4-(trifluoromethyl)phenyl]-2-propen-1-yl}oxy)phenoxy]phenyl}acetic acid,
- (2) {2-chloro-4-methyl-3-[3-({(2E)-3-[4-(trifluoromethyl)phenyl]-2-propen-1-yl}oxy)phenoxy]phenyl}acetic acid,
- (3) {2-methyl-3-[2-({(2E)-3-[4-(trifluoromethyl)phenyl]-2-propenyl}oxy)phenoxy]phenyl}acetic acid,
- (4) 2-chloro-4-methyl-3-[3-({(2E)-3-[4-(trifluoromethyl)phenyl]-2-propenyl}oxy)phenoxy]benzoic acid,
- (5) 3-methyl-5-[2-({(2E)-3-[4-(trifluoromethyl)phenyl]-2-propenyl}oxy)phenoxy]benzoic acid,
- (6) {3-methyl-5-[2-({(2E)-3-[4-(trifluoromethyl)phenyl]-2-propenyl}oxy)phenoxy]phenyl}acetic acid,
- (7) {3-[4-methyl-2-({(2E)-3-[4-(trifluoromethyl)phenyl]-2-propenyl}oxy)phenoxy]phenyl}acetic acid,
- (8) {3-[2-({3-[4-(trifluoromethyl)phenyl]-2-propynyl}oxy)phenoxy]phenyl}acetic acid,
- (9) 3-methyl-5-[4-methyl-2-({3-[4-(trifluoromethyl)phenyl]-2-propynyl}oxy)phenoxy]benzoic acid,
- (10) {3-methyl-5-[2-({3-[4-(trifluoromethyl)phenyl]-2-propynyl}oxy)phenoxy]phenyl}acetic acid,
- (11) {3-methyl-5-[4-methyl-2-({3-[4-(trifluoromethyl)phenyl]-2-propynyl}oxy)phenoxy]phenyl}acetic acid,
- (12) {3-methyl-5-[4-methyl-2-({(2E)-3-[4-(trifluoromethyl)phenyl]-2-propenyl}oxy)phenoxy]phenyl}acetic acid,
- (13) [3-(2-{{3-[4-chlorophenyl]-2-propynyl}oxy}phenoxy)phenyl]acetic acid,

- (14) {2-chloro-5-[2-({3-[4-(trifluoromethyl)phenyl]-2-propynyl}oxy)phenoxy]phenyl}acetic acid,
 - (15) {3-[2-chloro-6-({3-[4-(trifluoromethyl)phenyl]-2-propynyl}oxy)phenoxy]phenyl}acetic acid,
 - (16) 3-methyl-5-[4-methyl-2-({3-[6-(trifluoromethyl)-3-pyridinyl]-2-propynyl}oxy)phenoxy]benzoic acid,
 - (17) {3-[2-({(2E)-3-[4-(trifluoromethyl)phenyl]-2-propenyl}amino)phenoxy]phenyl}acetic acid,
 - (18) 3-(2-{{3-(4-chlorophenyl)-2-propynyl}oxy}phenoxy)-5-methylbenzoic acid,
 - (19) [3-(4-methyl-2-{{3-(4-methylphenyl)-2-propynyl}oxy}phenoxy)phenyl]acetic acid,
 - (20) [3-(2-{{3-(4-chlorophenyl)-2-propynyl}oxy}phenoxy)-5-methylphenyl]acetic acid,
 - (21) [3-methyl-5-(4-methyl-2-{{3-(4-methylphenyl)-2-propynyl}oxy}phenoxy)phenyl]acetic acid, and
 - (22) {3-methyl-5-[4-methyl-2-({3-[6-(trifluoromethyl)-3-pyridinyl]-2-propynyl}oxy)phenoxy]phenyl}acetic acid,
- or a salt thereof, a solvate thereof or a prodrug thereof.

8. **(Currently Amended)** A pharmaceutical composition comprising the compound according to claim 1, or a salt thereof, a solvate thereof or a prodrug thereof, and a pharmaceutically acceptable carrier.

9. **(Original)** The pharmaceutical composition according to claim 8, which is an agent for accelerating evacuation of lipid, an agent for reverse transport of lipid, an agent for inhibiting foam of macrophage, an agent for increasing HDL, an agent for decreasing LDL or an inhibitor of cholesterol biosynthesis.

10. **(Original)** The pharmaceutical composition according to claim 8, which is an agent for preventing and/or treating PPAR-mediated diseases.

11. **(Original)** The pharmaceutical composition according to claim 10, wherein PPAR is PPAR δ .

12. **(Original)** The pharmaceutical composition according to claim 11, wherein PPAR δ -mediated disease is hyperlipidemia or adiposity,

13. **(Original)** A medicament comprising the compound represented by formula (I) according to claim 1, a salt thereof, a solvate thereof or a prodrug thereof and one kind or more kinds selected from a MTP inhibitor, a HMG-CoA reductase inhibitor, a squalene synthase inhibitor, a fibrate drug, an ACAT inhibitor, a 5-lipoxygenase inhibitor, a cholesterol absorption inhibitor, a bile acid absorption inhibitor, an ideal Na⁺/bile acid transporter inhibitor, LDL receptor activator, LDL receptor expression enhancer, a pancreatic lipase inhibitor, a probucol formulation, a nicotine acid formulation and a cholesterol ester transporter protein inhibitor.

14. **(Original)** A method for accelerating evacuation of lipid in a mammal, which comprises administering to a mammal an effective amount of the compound represented by formula (I) according to claim 1, a salt thereof, a solvate thereof or a prodrug thereof.

Claim 15. **(Cancelled)**

16. **(Original)** A method for preventing and/or treating PPAR δ -mediated diseases in a mammal, which comprises administering to a mammal an effective amount of the compound represented by formula (I) according to claim 1, a salt thereof, a solvate thereof or a prodrug thereof.

Claim 17. **(Cancelled)**